Core Viewpoint - The company,尖峰集团, forecasts a significant increase in net profit for the year 2025, projecting approximately 460 million yuan, which represents a year-on-year increase of about 325.97% [1] Financial Performance - The expected net profit attributable to shareholders for 2025 is around 46,000 million yuan, an increase of approximately 35,201.19 million yuan compared to the previous year [1] - The substantial increase in net profit is primarily attributed to the sale of equity assets by its associate company, 天士力生物医药产业集团有限公司, which resulted in significant non-recurring income [1]

Core Viewpoint - The company expects a significant increase in net profit for the year 2025, projecting approximately 460 million yuan, which represents a year-on-year increase of about 325.97% compared to the previous year [1] Financial Performance - The projected net profit attributable to shareholders for 2025 is around 460 million yuan, an increase of approximately 352.01 million yuan compared to the previous year [1] - The substantial increase in net profit is primarily due to the non-recurring gains from the sale of equity assets by the company's equity-accounted affiliate, Tian Shili Group [1] Non-Recurring Gains - The profit increase is largely attributed to non-recurring income from the sale of equity assets by Tian Shili Group, which significantly boosted the reported profits for the period [1]

证券代码：600668 证券简称：尖峰集团 公告编号：临 2026-003 浙江尖峰集团股份有限公司 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本期业绩预告适用于实现盈利，且净利润与上年同期相比上升 50%以上 的情形。 2025 年 1 月 1 日至 2025 年 12 月 31 日。 浙江尖峰集团股份有限公司（以下简称"本公司"）预计 2025 年年度实 现归属于上市公司股东的净利润 46,000 万元左右，与上年同期相比，将增加 35,201.19 万元左右，同比增加 325.97%左右。 预计 2025 年年度实现归属于上市公司股东的扣除非经常性损益的净利 润-21,500 万元左右，与上年同期相比，将减少 31,161.77 万元左右，同比减少 322.53%左右。 一、本期业绩预告情况 （一）业绩预告期间 （二）业绩预告情况 1、经财务部门初步测算，预计 2025 年年度实现归属于上市公司股东的净利 润 46,000 万元左右，与上年同期相比，将增加 35,201 ...

Core Viewpoint - The company expects a significant increase in net profit attributable to shareholders for the year 2025, while the net profit excluding non-recurring gains and losses is projected to decrease substantially [1][2]. Group 1: Financial Projections - The company anticipates achieving a net profit of approximately 460 million yuan for the year 2025, which represents an increase of about 352 million yuan, or a growth of approximately 325.97% compared to the previous year [1]. - The expected net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be around -21.5 million yuan, indicating a decrease of about 31.2 million yuan, or a decline of approximately 322.53% year-on-year [1]. Group 2: Reasons for Performance Changes - The significant increase in net profit is primarily due to the equity method accounting for the joint venture Tian Shili Biological Pharmaceutical Industry Group Co., Ltd., which sold its equity assets, resulting in substantial profit growth from non-recurring gains [2]. - The company has been actively implementing energy-saving and consumption-reduction modifications and strictly controlling product costs; however, the prices and sales volumes of cement and clinker products have decreased year-on-year [2]. - The pharmaceutical segment has faced challenges due to policies such as drug procurement and price reductions, as well as a continuous decline in pesticide market prices, leading to decreased prices and sales volumes of major products [2]. - The company’s subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd., has terminated the clinical trial and subsequent development of the injectable deoxynojirimycin project, resulting in a full impairment provision of 18.2141 million yuan for the development costs, which will reduce the total profit for 2025 [2].

每经AI快讯，1月27日，尖峰集团(600668.SH)公告称，预计2025年归属于上市公司股东的净利润为4.60 亿元左右，同比增加325.97%左右。业绩变动主要原因是联营企业天士力集团出售股权资产产生大额非 经常性收益。 ...

尖峰集团公告，预计2025年年度实现归属于上市公司股东的净利润4.6亿元左右，与上年同期相比，将 增加3.52亿元左右，同比增加325.97%左右。预计2025年年度实现归属于上市公司股东的扣除非经常性 损益的净利润-2.15亿元左右，与上年同期相比，将减少3.12亿元左右，同比减少322.53%左右。 ...

Group 1 - The cement sector experienced a decline of 0.92% on January 16, with Jinyu Group leading the drop [1] - The Shanghai Composite Index closed at 4101.91, down 0.26%, while the Shenzhen Component Index closed at 14281.08, down 0.18% [1] - Key stocks in the cement sector showed varied performance, with Xizang Tianlu rising by 3.02% to a closing price of 11.25, while Jinyu Group fell by 9.95% to 1.90 [1][2] Group 2 - The cement sector saw a net inflow of 126 million yuan from institutional investors, while retail investors experienced a net outflow of 161 million yuan [2] - The trading volume for Xizang Tianlu was 1.2037 million hands, with a transaction value of 1.37 billion yuan, indicating strong interest despite the overall sector decline [1][2] - The main capital inflow was concentrated in stocks like Xizang Tianlu and Guotong Shares, with net inflows of 207 million yuan and 16.56 million yuan respectively [3]

Core Viewpoint - Zhejiang Jianfeng Group Co., Ltd. announced that its subsidiary, Jianfeng Pharmaceutical, has voluntarily withdrawn the clinical trial application for the drug "C2235 and C2235 tablets" to the National Medical Products Administration, pending further research and will resubmit the application at a later date [2][3]. Group 1: Drug Registration and Withdrawal - Jianfeng Pharmaceutical received a termination notice for the drug registration application for "C2235 and C2235 tablets" from the National Medical Products Administration, indicating that the withdrawal was a proactive decision by the company [2]. - The withdrawal was due to the need for further improvement of the application materials during the registration process [2]. Group 2: Impact on Company Performance - The withdrawal of the clinical trial application for "C2235 and C2235 tablets" is not expected to have a significant impact on the company's current performance [3]. - The company acknowledges that the research and development of innovative drugs involve high technology and risks, with long and complex cycles from development to production, which are susceptible to unpredictable factors [3].

Group 1 - Siyuan Electric reported a total operating revenue of 21.205 billion yuan for 2025, a year-on-year increase of 37.18%, with a net profit attributable to shareholders of 3.163 billion yuan, up 54.35% year-on-year [1] - VisiOn expects a negative net profit for 2025, indicating a loss in operating performance [2] - Chongqing Steel anticipates a net loss of 2.5 billion to 2.8 billion yuan for 2025, which is an improvement from a net loss of 3.196 billion yuan in the previous year [3] - Lianfa Co. forecasts a net profit of 280 million to 320 million yuan for 2025, representing a year-on-year growth of 38.92% to 58.77% [4] Group 2 - CICC announced that the audit work related to the absorption merger with Dongxing Securities and Xinda Securities has not yet been completed [5] - Dalong Real Estate's subsidiary won a project bid worth 763 million yuan [6] - Zhongchuang Zhiling plans to issue convertible bonds to raise no more than 4.35 billion yuan for various projects [7] - Jintong Co. intends to acquire a 24% stake in Jinsha Molybdenum for 1.731 billion yuan [8] Group 3 - Nami Technology expects a net profit of 128 million to 145 million yuan for 2025, an increase of 54.51% to 75.03% year-on-year [9] - China State Construction reported a new contract total of 4.5458 trillion yuan for 2025, a 1% increase year-on-year [12] - China Metallurgical Group's new contract amount for 2025 is expected to decrease by 10.8% to 1.1136 trillion yuan [13] Group 4 - Beiding Co. reported a net profit of 111 million yuan for 2025, a year-on-year increase of 59.05% [14] - Southwest Securities expects a net profit of 1.028 billion to 1.098 billion yuan for 2025, an increase of 47% to 57% [15] - China Eastern Airlines reported a 4.93% year-on-year increase in passenger capacity for December 2025 [20] Group 5 - *ST Aowei's stock may be delisted due to a closing price below par value [21] - Yilian Network expects a net profit of 2.542 billion to 2.648 billion yuan for 2025, a decrease of 0% to 4% year-on-year [22] - Huochen Co. anticipates a net profit of 420 million to 540 million yuan for 2025, recovering from a loss of 2 million yuan in the previous year [17] Group 6 - Guoli Electronics expects a net profit of 68 million to 80 million yuan for 2025, an increase of 124.89% to 164.57% [28] - Jinchuan Group forecasts a net profit of 11 billion to 12 billion yuan for 2025, a year-on-year increase of 73.57% to 89.34% [41] - Triangle Tire plans to invest 3.219 billion yuan in a new tire project in Cambodia [42]

Core Viewpoint - Jianfeng Group's subsidiary, Jianfeng Pharmaceutical, has voluntarily withdrawn its drug registration clinical trial application for "C2235 and C2235 tablets" due to the need for further documentation improvement [1] Group 1: Company Actions - Jianfeng Pharmaceutical received a termination notice from the National Medical Products Administration regarding the drug registration application [1] - The decision to withdraw the application was made after careful consideration, indicating a proactive approach to ensure compliance and quality [1] Group 2: Future Plans - The company plans to resubmit the drug registration clinical trial application after completing the necessary research improvements [1]